Tags

Type your tag names separated by a space and hit enter

Osteoporosis in men: an Endocrine Society clinical practice guideline.
J Clin Endocrinol Metab. 2012 Jun; 97(6):1802-22.JC

Abstract

OBJECTIVE

The aim was to formulate practice guidelines for management of osteoporosis in men.

EVIDENCE

We used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and evidence quality.

CONSENSUS PROCESS

Consensus was guided by systematic evidence reviews, one in-person meeting, and multiple conference calls and e-mails. Task Force drafts were reviewed successively by The Endocrine Society's Clinical Guidelines Subcommittee and Clinical Affairs Core Committee; representatives of ASBMR, ECTS, ESE, ISCD; and members at large. At each stage, the Task Force received written comments and incorporated needed changes. The reviewed document was approved by The Endocrine Society Council before submission for peer review.

CONCLUSIONS

Osteoporosis in men causes significant morbidity and mortality. We recommend testing higher risk men [aged ≥70 and men aged 50-69 who have risk factors (e.g. low body weight, prior fracture as an adult, smoking, etc.)] using central dual-energy x-ray absorptiometry. Laboratory testing should be done to detect contributing causes. Adequate calcium and vitamin D and weight-bearing exercise should be encouraged; smoking and excessive alcohol should be avoided. Pharmacological treatment is recommended for men aged 50 or older who have had spine or hip fractures, those with T-scores of -2.5 or below, and men at high risk of fracture based on low bone mineral density and/or clinical risk factors. Treatment should be monitored with serial dual-energy x-ray absorptiometry testing.

Authors+Show Affiliations

Mercy Health Osteoporosis & Bone Health Services, Cincinnati Ohio 45236, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Practice Guideline

Language

eng

PubMed ID

22675062

Citation

Watts, Nelson B., et al. "Osteoporosis in Men: an Endocrine Society Clinical Practice Guideline." The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 6, 2012, pp. 1802-22.
Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(6):1802-22.
Watts, N. B., Adler, R. A., Bilezikian, J. P., Drake, M. T., Eastell, R., Orwoll, E. S., & Finkelstein, J. S. (2012). Osteoporosis in men: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 97(6), 1802-22. https://doi.org/10.1210/jc.2011-3045
Watts NB, et al. Osteoporosis in Men: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2012;97(6):1802-22. PubMed PMID: 22675062.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Osteoporosis in men: an Endocrine Society clinical practice guideline. AU - Watts,Nelson B, AU - Adler,Robert A, AU - Bilezikian,John P, AU - Drake,Matthew T, AU - Eastell,Richard, AU - Orwoll,Eric S, AU - Finkelstein,Joel S, AU - ,, PY - 2012/6/8/entrez PY - 2012/6/8/pubmed PY - 2012/8/16/medline SP - 1802 EP - 22 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 97 IS - 6 N2 - OBJECTIVE: The aim was to formulate practice guidelines for management of osteoporosis in men. EVIDENCE: We used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and evidence quality. CONSENSUS PROCESS: Consensus was guided by systematic evidence reviews, one in-person meeting, and multiple conference calls and e-mails. Task Force drafts were reviewed successively by The Endocrine Society's Clinical Guidelines Subcommittee and Clinical Affairs Core Committee; representatives of ASBMR, ECTS, ESE, ISCD; and members at large. At each stage, the Task Force received written comments and incorporated needed changes. The reviewed document was approved by The Endocrine Society Council before submission for peer review. CONCLUSIONS: Osteoporosis in men causes significant morbidity and mortality. We recommend testing higher risk men [aged ≥70 and men aged 50-69 who have risk factors (e.g. low body weight, prior fracture as an adult, smoking, etc.)] using central dual-energy x-ray absorptiometry. Laboratory testing should be done to detect contributing causes. Adequate calcium and vitamin D and weight-bearing exercise should be encouraged; smoking and excessive alcohol should be avoided. Pharmacological treatment is recommended for men aged 50 or older who have had spine or hip fractures, those with T-scores of -2.5 or below, and men at high risk of fracture based on low bone mineral density and/or clinical risk factors. Treatment should be monitored with serial dual-energy x-ray absorptiometry testing. SN - 1945-7197 UR - https://www.unboundmedicine.com/medline/citation/22675062/Osteoporosis_in_men:_an_Endocrine_Society_clinical_practice_guideline_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2011-3045 DB - PRIME DP - Unbound Medicine ER -